NTHI (NeOnc Technologies Holdings) Marketable Securities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $3.44
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings Marketable Securities?

NeOnc Technologies Holdings NTHI +6.46% 7 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NeOnc Technologies Holdings's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

NeOnc Technologies Holdings  (NAS:NTHI) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NeOnc Technologies Holdings Marketable Securities Related Terms

NeOnc Technologies Holdings Marketable Securities Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings Marketable Securities Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00 0.00 0.00

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
NeOnc Technologies Holdings (NTHI) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeOnc Technologies Holdings and its competitors.
Is NeOnc Technologies Holdings' Marketable Securities too high?
NeOnc Technologies Holdings' current Marketable Securities is $0.00 Mil. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' Marketable Securities compare to GUTS and PEPG?
NeOnc Technologies Holdings' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.44
Price